Press release
ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ ESCLC Pipeline Outlook Report [https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the ESCLC Pipeline Report
* In August 2025, Bristol-Myers Squibb announced a study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
* In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
* In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.
* DelveInsight's ESCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for ESCLC treatment.
* The leading ESCLC Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
* Promising ESCLC Pipeline Therapies such as LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others.
Learn how leading ESCLC Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ ESCLC Clinical Trials Assessment [https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
ESCLC Emerging Drugs Profile
* Serplulimab+Chemo: Shanghai Henlius Biotech
Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase III clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase III clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. Currently, the drug is in Phase III stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).
* Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3. Currently, the drug is in Phase II stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).
* RYZ101: RayzeBio, Inc.
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. RYZ101 is being combined with current standard of care therapy. Currently, the drug is in Phase I stage of its development for the treatment of of Extensive-Stage Small Cell Lung Cancer (ESCLC).
The ESCLC Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of ESCLC with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESCLC Treatment.
* ESCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* ESCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESCLC market.
From early-stage research to late-phase ESCLC Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ ESCLC Treatment Drugs [https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
ESCLC Companies
Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
ESCLC Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Stay updated with the latest ESCLC Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ ESCLC Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the ESCLC Pipeline Report
* Coverage- Global
* ESCLC Companies- Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
* ESCLC Pipeline Therapies- LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others.
* ESCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* ESCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest ESCLC Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ ESCLC Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Extensive Stage Small Cell Lung Cancer (ESCLC): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Extensive-Stage Small Cell Lung Cancer (ESCLC) - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Serplulimab+Chemo: Shanghai Henlius Biotech
* Mid-Stage Products (Phase II)
* Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
* Early Stage Products (Phase I)
* RYZ101: RayzeBio, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
* Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products
* Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs
* Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers
* Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion
* Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views
* Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esclc-pipeline-assessment-report-2025-key-25-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4140726 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for SCLC
Urban Edge Network Partners with SCLC for Social Justice and Economic Empowermen …
Image: https://www.abnewswire.com/upload/2025/07/02659c90ee7c5fd7ba17d849d467eb47.jpg
July 3, 2025 - Atlanta, GA - Urban Edge Network (UEN), a leading Black-owned sports and lifestyle media company, is proud to announce a groundbreaking partnership with the Southern Christian Leadership Conference (SCLC), one of the most storied civil rights organizations in American history. This collaboration aims to advance economic equity and social justice by harnessing the power of media, advertising, and community action.
The strategic alliance is designed to…
Small Cell Lung Cancer (SCLC) Therapeutics Market Research & Outlook 2020
Impact Analysis of Coronavirus Disease (Covid-19) on Small Cell Lung Cancer (SCLC) Therapeutics Market
Facto Market Insights published a title on “Small Cell Lung Cancer (SCLC) Therapeutics Market – 2020-2026”, to its collection. The study on the small cell lung cancer (SCLC) therapeutics market defines the analysis of all the segments, along with the market sizing, year-over-year growth analysis and structure of the industry. The research report also includes the analysis…
OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Fo …
Researchmoz added Most up-to-date research on "OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024" to its huge collection of research reports.
Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung…
Overview of Small cell lung cancer (SCLC) Industry : Market Development, Analysi …
ALBANY, NY, April 5, 2017 : ResearchMoz presents professional and in-depth study of "Small cell lung cancer (SCLC)- Market Insights, Epidemiology and Market Forecast-2023".
DelveInsights Small cell lung cancer (SCLC) - Market Insights, Epidemiology and Market Forecast-2023 Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers…
Small cell lung cancer (SCLC)- Market Insights, Epidemiology and Market Forecast …
DelveInsights Small cell lung cancer (SCLC) - Market Insights, Epidemiology and Market Forecast-2023 Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Small cell lung cancer (SCLC) forecasted market share for ten years to 2023…
Small Cell Lung Cancer (SCLC) Treatment Market Revenue and Value Chain 2016-2026
According to the World Health Organization (WHO), 8.2 million people died from cancer around the world in 2012, and cancer is now one of the leading causes of death. Lung cancer is the leading cancer type and caused 1.59 million deaths in 2012.
Small cell lung cancer is two types -
Oat cancer
Combiner small cell cancer
The major risk factors for small cell lung…
